Acadia Pharmaceuticals Presents Clinical Data from Across Multiple Therapeutic Programs at the 2025 International Congress of Parkinson's Disease and Movement Disorders®

Core Insights - Acadia Pharmaceuticals Inc. announced presentations at the International Congress of Parkinson's Disease and Movement Disorders, showcasing updates from its pipeline [1] Group 1: Presentations - The company will present one late-breaker oral platform presentation and two poster presentations [1] - The presentations will take place from October 5-9, 2025, in Honolulu, Hawaii [1] Group 2: Pipeline Updates - The presentations will highlight preclinical efficacy, safety, and mechanism of action findings related to Acadia's investigational drug ACP-711 [1]